Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.
Nicholas W BatemanTamara AbulezAnthony R SoltisAndrew McPhersonSeongmin ChoiDale W GarsedAhwan PandeyChunqiao TianBrian L HoodKelly A ConradsPang-Ning TengJulie OliverGlenn GistDave MitchellTracy J LitziChristopher M TarneyBarbara A CrothersPaulette Mhawech-FaucegliaCliffton L DalgardMatthew D WilkersonMariaelena PierobonEmanuel F PetricoinChunhua YanDaoud MeerzamanClara BodelonNicolas WentzensenJerry S H Leenull nullDavid G HuntsmanSohrab P ShahCraig D ShriverNeil T PhippenKathleen M DarcyDavid D L BowtellThomas P ConradsG Larry MaxwellPublished in: NPJ precision oncology (2024)
We performed a deep proteogenomic analysis of bulk tumor and laser microdissection enriched tumor cell populations from high-grade serous ovarian cancer (HGSOC) tissue specimens spanning a broad spectrum of purity. We identified patients with longer progression-free survival had increased immune-related signatures and validated proteins correlating with tumor-infiltrating lymphocytes in 65 tumors from an independent cohort of HGSOC patients, as well as with overall survival in an additional 126 HGSOC patient cohort. We identified that homologous recombination deficient (HRD) tumors are enriched in pathways associated with metabolism and oxidative phosphorylation that we validated in independent patient cohorts. We further identified that polycomb complex protein BMI-1 is elevated in HR proficient (HRP) tumors, that elevated BMI-1 correlates with poor overall survival in HRP but not HRD HGSOC patients, and that HRP HGSOC cells are uniquely sensitive to BMI-1 inhibition.